You have 9 free searches left this month | for more free features.

recurrent metastatic squamous neck cancer with occult primary

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2022

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With

Completed
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +35 more
  • PI3K inhibitor BKM120
  • cetuximab
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Sep 14, 2021

Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma Trial (Ficlatuzumab,

Not yet recruiting
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • Ficlatuzumab
  • +2 more
  • (no location specified)
Sep 26, 2023

Head and Neck Squamous Cell Carcinoma Trial in Shanghai (BL-B01D1, SI-B003)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 17, 2023

Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 9, 2023

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer Trial (Tislelizumab, BGB-A425, LBL-007)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Cancer
  • (no location specified)
Jun 9, 2023

Head Neck, Squamous Cell Carcinoma of Head and Neck Trial in Houston (Pembrolizumab, Magrolimab, cetuximab)

Not yet recruiting
  • Head Neck
  • Squamous Cell Carcinoma of Head and Neck
  • Houston, Texas
    M D Anderson Cancer Center
Sep 14, 2023

Recurrent Head Neck Cancer, Head Neck Cancer, Head and Neck Tumors Trial in Cincinnati (Durvalumab, Cetuximab)

Active, not recruiting
  • Recurrent Head and Neck Cancer
  • +3 more
  • Cincinnati, Ohio
    UC Health
Oct 3, 2022

Sinonasal Cancer, Squamous NSCLC, Lung Cancer Trial run by the National Cancer Institute (NCI) (pembrolizumab, valemetostat)

Not yet recruiting
  • Sinonasal Cancer
  • +5 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 5, 2023

Head Neck Cancer, Squamous Cell Carcinoma of the Head and Neck Trial in La Jolla (Ibrutinib 560mg PO daily (Imbruvica),

Active, not recruiting
  • Head and Neck Cancer
  • Squamous Cell Carcinoma of the Head and Neck
  • Ibrutinib 560mg PO daily (Imbruvica)
  • +2 more
  • La Jolla, California
    UCSD Moores Cancer Center
Jan 11, 2023

Head and Neck Squamous Cell Cancer Trial (pembrolizumab, methotrexate, docetaxel)

Completed
  • Head and Neck Squamous Cell Cancer
  • pembrolizumab
  • +3 more
  • (no location specified)
Aug 24, 2022

Head Neck Cancer Trial in Charleston (Pembrolizumab, Clopidogrel, acetylsalicylic acid)

Recruiting
  • Head and Neck Cancer
  • Charleston, South Carolina
    Medical University of South Carolina
Dec 22, 2022

Recurrent Head and Neck Squamous Cell Carcinoma Trial in Atlanta, Cleveland, Milwaukee (IMRT, Nivolumab)

Active, not recruiting
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • IMRT
  • Nivolumab
  • Atlanta, Georgia
  • +3 more
Jan 10, 2023

Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint

Not yet recruiting
  • Recurrent Head and Neck Cancer
  • +5 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 30, 2023

Head Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck Trial

Not yet recruiting
  • Head and Neck Cancer
  • +4 more
  • Ozuriftamab Vedotin
  • PD-1 inhibitor
  • (no location specified)
Jul 28, 2022

Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oral Cavity

Active, not recruiting
  • Squamous Cell Carcinoma of the Oropharynx
  • +7 more
  • Tampa, Florida
  • +2 more
Dec 30, 2022

Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin Trial in Australia, United States (TH-4000)

Terminated
  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • TH-4000 (Tarloxotinib)
  • Los Angeles, California
  • +9 more
Jan 9, 2023

Head and Neck Squamous Cell Carcinoma Trial (TTI-101, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Dec 20, 2022

Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous

Active, not recruiting
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • +3 more
  • 200 mg Pembrolizumab
  • +2 more
  • Miami, Florida
  • +6 more
Jan 9, 2023

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Trial in Pittsburgh (Pembrolizumab, Carboplatin,

Not yet recruiting
  • Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 18, 2023

Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (Tazemetostat, Pembrolizumab)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Saint Louis, Missouri
    Washington University School of Medicine
Oct 26, 2022

Following Salvage Surgery for RESidual or reCurrent sqUamous

Not yet recruiting
  • Head and Neck Cancer
  • Molecular Analyses
  • (no location specified)
Mar 28, 2023

Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +23 more
  • Biospecimen Collection
  • +2 more
  • Los Angeles, California
  • +1 more
Jul 7, 2022

Head and Neck Squamous Cell Carcinoma, Head Neck Cancer, Head Neck Cancer Metastatic Trial in Baltimore (Nivolumab 480mg and

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
  • Nivolumab 480mg and surgical resection
  • Baltimore, Maryland
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Feb 25, 2022